Campbell & Co Investment Adviser’s Protagonist Therapeutics PTGX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$761K	Buy	+6,206	New	+$648K	0.04%	643
2026 Q1	–	Sell	-21,054	Closed	-$1.84M	–	1356
2025 Q4	$1.84M	Buy	+21,054	New	+$1.72M	0.09%	357
2025 Q2	–	Sell	-19,015	Closed	-$920K	–	1406
2025 Q1	$920K	Buy	+19,015	New	+$797K	0.07%	464
2024 Q2	–	Sell	-13,763	Closed	-$398K	–	1289
2024 Q1	$398K	Buy	+13,763	New	+$374K	0.03%	803
2023 Q4	–	Sell	-56,577	Closed	-$944K	–	1292
2023 Q3	$944K	Buy	56,577 +36,019	+175%	+$699K	0.11%	291
2023 Q2	$568K	Buy	+20,558	New	+$515K	0.1%	370

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Campbell & Co Investment Adviser's PTGX Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 6,206 shares worth $761K. The stake represents 0.04% of the portfolio and ranks #643 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in PTGX as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in PTGX in Q2 2023 and has held it in 6 quarters since. The position peaked at $1.84M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Campbell & Co Investment Adviser held 6,206 shares of Protagonist Therapeutics worth $761K as of Q2 2026.
Protagonist Therapeutics was a new Campbell & Co Investment Adviser position in Q2 2026.
Protagonist Therapeutics made up 0.04% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #643 holding.
Campbell & Co Investment Adviser first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 6 quarters since.
Campbell & Co Investment Adviser's Protagonist Therapeutics position peaked at $1.84M in Q4 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.